Medtronic's Contrarian Role

With competitors looking for ever bigger deals, Medtronic is clearly playing the contrarian role. Will Medtronic ever feel pressured to go along?

In the last year no industry segment made more news in high-valuation acquisitions than cardiovascular devices. But until now, the companies making news have been Boston Scientific, St. Jude and J&J. Curiously silent has been Medtronic.

The BSC, J&J, and St. Jude deals have all been large-scale acquisitions designed to create new platforms on which the...

More from Archive

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.